Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06024174 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT06024174 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 5 participants.
The verdict
NCT06024174, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC), pancreatic duct adenocarcinoma (PDAC), biliary tract cancer (BTC), or colorectal cancer (CRC).
Interventions
- DRUG Cetuximab
- DRUG Adagrasib
- DRUG BMS-986466
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2024-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06024174
The ClinicalTrials.gov registry entry for NCT06024174 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cetuximab is the first listed.
NCT06024174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06024174 about?
NCT06024174 is a clinical study titled "A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors". The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC), pancreatic duct adenocarcinoma (PDAC), biliary trac...
What is the current status of trial NCT06024174?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2023-11-09. Estimated completion is 2024-05-13.
What interventions are being tested in trial NCT06024174?
The interventions under investigation include: Cetuximab (DRUG), Adagrasib (DRUG), BMS-986466 (DRUG).
Who is sponsoring clinical trial NCT06024174?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.